HYDERABAD, India--(BUSINESS WIRE)--Platrol® has demonstrated 40% more efficacy and negligible toxicity in limited clinical trials resulting in higher therapeutic index compared to Aspirin, Clopidogrel and other anti-platelet drugs. And Platrol®’s inherent sustained release property makes it even better as a long-term cardio-protective drug.
